<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565171</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DDAG181PA-18-001</org_study_id>
    <nct_id>NCT04565171</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD</brief_title>
  <official_title>A Single-center, Non-randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and End-stage Renal Disease Without Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the single-dose pharmacokinetics (PK) and safety of Yimitasvir&#xD;
      phosphate capsule in participants with End-stage renal disease without hemodialysis using&#xD;
      matched healthy participants as a control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">October 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 27, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters of DAG181 as measured by AUC</measure>
    <time_frame>From Days 1-5</time_frame>
    <description>AUC is defined as the concentration of drug area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics (PK) parameters of DAG181 as measured by Cmax</measure>
    <time_frame>From Days 1-5</time_frame>
    <description>Cmax is defined as the maximum concentration of drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From Days 1-5</time_frame>
    <description>The incidence of adverse events will be summarized</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Participants with renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with End-stage renal disease will receive a single dose of Yimitasvir Phosphate Capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal renal function will receive a single dose of Yimitasvir Phosphate Capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yimitasvir Phosphate Capsule</intervention_name>
    <description>DAG181 100 mg (100 mg Capsule) administered orally</description>
    <arm_group_label>Participants with normal renal function</arm_group_label>
    <arm_group_label>Participants with renal impairment</arm_group_label>
    <other_name>DAG181</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female, age 18 to 70 years of age, inclusive;&#xD;
&#xD;
          2. must have a calculated body mass index (BMI) from 18 to 28 kg/m2 at study screening;&#xD;
&#xD;
          3. Glomerular filtration rate must be &lt; 15 mL/min /1.73 m2 for End-stage renal disease&#xD;
             without hemodialysis group, and ≥ 90 mL/min for Normal Renal Function group(using MDRD&#xD;
             method);&#xD;
&#xD;
          4. matched for age (±5 years) ,gender and BMI(±15%) with a subject in the End-stage renal&#xD;
             disease without hemodialysis group;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. allergies constitution ( multiple drug and food allergies);&#xD;
&#xD;
          2. Use of &gt;5 cigarettes per day during the past 3 months;&#xD;
&#xD;
          3. A positive test results for HbsAg, Hepatitis C antibody, HIV-1 antibody, or Treponema&#xD;
             pallidum antibody；&#xD;
&#xD;
          4. History of alcohol abuse；&#xD;
&#xD;
          5. Donation or loss of blood over 400 mL within 3 months prior to the first dose of study&#xD;
             drug；&#xD;
&#xD;
          6. Subjects deemed unsuitable by the investigator for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jia Miao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jia Miao, Doctor</last_name>
    <phone>028-85422622</phone>
    <email>miaosiyi1971@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiao Miao, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yimitasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

